19 Jun 2014 07:00
19 June 2014
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Venn's first skin science patent grant ignites Innovenn's commercialisation stage
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that its innovation division, Innovenn, has secured its first skin science patent for its unique anti-acne complex from the European Patent Office. The Company has also commenced commercial discussions on Labskin, the breakthrough research grade human skin testing platform.
This clinically proven Blemish Control Technology, developed by dermatologists over five years of scientific research, clinical and home usage trials, uniquely delivers a natural blend of actives deeper and faster into the epidermal skin layer than other commercially available treatments. The active complex reduces bacteria, inflammation, excess oiliness and blocked pores, resulting in noticeably clearer skin in less than four hours.
This breakthrough enables a compelling scientific platform for the commercial development of a new blemish management technology brand, expected to launch later this year.
Meanwhile, commercial partnership discussions have commenced on Labskin following the establishment of new Innovenn laboratories and offices on the Innovation Campus at Sand Hutton, UK and the recruitment of a skin science management team. First revenue flows from Labskin are expected later this year.
Tony Richardson, CEO of Venn Life Sciences commented: "After five years of dermatological research, testing and consumer trials, this patent grant confirmation from the European Patent office is a substantial step forward in the commercialisation of this unique anti-acne complex. Since our acquisition of the assets of Evocutis Plc. in March of 2014, Innovenn have made tremendous progress in terms of bringing our anti-acne and living skin equivalent technology to the marketplace."
Enquiries:
Venn Life Sciences Holdings Plc | www.vennlifesciences.com |
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 |
Declan Service, Managing Director Orla McGuinness, Marketing Manager | Tel: +353 877705506 |
Zeus Capital (Nominated Adviser and Broker) | |
Ross Andrews/Andrew Jones (Corporate Finance) | Tel: 0161 831 1512 |
Dominic Wilson (Institutional Sales) | Tel: 020 7533 7727 |
Walbrook PR Ltd | Tel: 020 7933 8787 or venn@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
About InnoVenn
InnoVenn is a market development accelerator dedicated to rapidly commercializing proven scientific breakthroughs in the form of products and technologies primarily in Skin Science. These include labskin the breakthrough research grade human skin testing platform as well as the clinically proven Blemish Control Technology for the professional skincare market. For more information on Innovenn, visit www.innovenn.co.uk
About Venn Life Sciences Limited
Venn Life Sciences is a Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK and Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.